Understanding how a specific molecule affects inflammation in Alzheimer's disease
Official title: Deciphering the role of junctional adhesion molecule-A in neutrophil-driven inflammatory response in Alzheimer disease
Funded at University of Michigan at Ann Arbor · NIH-11087579 · Data updated 2026-11-12
This study is looking at how a protein called JAM-A affects inflammation in Alzheimer's disease by examining how certain white blood cells behave, with the hope of finding new ways to reduce inflammation and support brain health for people with Alzheimer's.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | August 15, 2023 |
| Project end | April 1, 2028 |
| Funding year | 2025 |
| Award (this year) | $623,382 |
| NIH project number | 5R01AG084186-03 |
| Project ID | NIH-11087579 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those at risk of developing it, particularly those experiencing cognitive decline.
✕Less likely to help
Patients with other forms of dementia or neurological conditions unrelated to Alzheimer's disease may not benefit from this research.
What this research studies
This research investigates the role of junctional adhesion molecule-A (JAM-A) in the inflammatory response associated with Alzheimer's disease (AD). It focuses on how neutrophils, a type of white blood cell, contribute to inflammation in both the brain and blood, potentially leading to cognitive decline. By manipulating JAM-A and observing its effects on neutrophil behavior in a mouse model of AD, the study aims to uncover mechanisms that could help reduce inflammation and improve brain health. The findings could provide insights into new therapeutic strategies for managing Alzheimer's disease.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that reduce inflammation in the brains of Alzheimer's patients, potentially slowing disease progression and improving cognitive function.
How similar studies have gone: Other research has shown promising results in targeting inflammatory processes in Alzheimer's disease, suggesting that this approach could be effective.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Andjelkovic-Zochowska, Anuska V. — University of Michigan at Ann Arbor
- Study coordinator: Andjelkovic-Zochowska, Anuska V.
Related research
Other NIH-funded projects on the same topics.
-
Understanding how a brain barrier molecule affects neutrophil-driven brain inflammation in Alzheimer’s
A patient-focused look at how a molecule that helps immune cells stick to brain blood vessels might influence inflammation and progression in Alzheimer’s disease.
-
SSRI use during pregnancy: effects on placental blood flow and inflammation
This grant studies how antidepressants (SSRIs) used during pregnancy might affect the placenta and inflammation, and whether a 5-HT2 receptor blocker could mitigate any negative effects.
-
Mitochondrial energy problems in men and women with Alzheimer’s disease
This grant tests how mitochondria differ between men and women with Alzheimer's disease to find ways to tailor care.
-
Mitochondrial energy problems in people with Alzheimer’s and related brain diseases
A research effort is looking at how mitochondrial energy problems differ between men and women with Alzheimer’s disease and related dementias and what this means for future care.
-
Understanding Alzheimer's Genetic Risk in African and Admixed African-American People
A study looks at genetic factors and biomarkers to understand why Alzheimer's disease affects African and admixed African-American communities differently.
-
Genetic Risk for Alzheimer’s in African and admixed African-American communities
Researchers will study how genes influence Alzheimer’s risk in people of African ancestry to better understand why the disease affects diverse communities differently.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.